Suchergebnisse - "Cappello, Maria"

PubPharm (14)

1

An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors

enthalten in: The American journal of gastroenterology | 2022

von Onali, S. | Pugliese, D. | Caprioli, F. | +28

2

Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease : the IG-IBD LIVE study

enthalten in: Alimentary pharmacology & therapeutics | 2022

von Pugliese, D. | Privitera, G. | Crispino, F. | +58

CommentIn: Aliment Pharmacol Ther. 2022 Aug;56(4):731-732. - PMID 35879894

3

Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2022

von Macaluso, F. | Cappello, M. | Crispino, F. | +18

4

A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease

enthalten in: Journal of gastroenterology and hepatology | 2021

von Macaluso, F. | Ventimiglia, M. | Fries, W. | +19

5

A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2020

von Macaluso, F. | Ventimiglia, M. | Fries, W. | +20

6

Effectiveness and safety of vedolizumab in biologically naïve patients : A real-world multi-centre study

enthalten in: United European gastroenterology journal | 2020

von Macaluso, F. | Fries, W. | Renna, S. | +17

7

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

enthalten in: The New England journal of medicine | 2019

von Sands, B. | Peyrin-Biroulet, L. | Loftus, E. | +111

CommentIn: N Engl J Med. 2019 Sep 26;381(13):1279-1281. - PMID 31553842

8

Inflammatory Bowel Disease Onset During Secukinumab Treatment : Real Concern or Just an Expression of Dysregulated Immune Response?

enthalten in: Clinical drug investigation | 2019

von Fries, W. | Belvedere, A. | Cappello, M. | +2

9

Response to "The combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous Anti-TNF alfa failure"

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2018

von Scrivo, B. | Vitello, A. | Cappello, M.

CommentOn: Dig Liver Dis. 2018 Apr;50(4):415-417. - PMID 29397323

10

The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2018

von Macaluso, F. | Orlando, R. | Fries, W. | +15